Abstract: Therapeutic use of oligodeoxynucleotides (ODNs) that hybridize to and downregulate target mRNAs encoding proteins that contribute to malignant transformation has a sound rationale, but has had an overall limited clinical success in cancer due to insufficient intracellular delivery. Here we report a development of formulations capable of promoting targeted delivery and enhanced pharmacologic activity of ODNs in acute myeloid leukemia (AML) cell lines and patient primary cells. In this study, transferrin (Tf) conjugated pH-sensitive lipopolyplex nanoparticles (LPs) were prepared to deliver GTI-2040, an antisense ODN against the R2 subunit of ribonucleotide reductase that has been shown to contribute to chemoresistance in AML. LPs had an average particle size around 110 nm and a moderately positive zeta potential at ∼ 10 mV. The ODN encapsulation efficiency of LPs was >90%. These nanoparticles could release ODNs at acidic endosomal pH and facilitate the cytoplasmic delivery of ODNs after endocytosis. In addition, Tf-mediated targeted delivery of GTI-2040 was achieved. R2 downregulation at both mRNA and protein levels was improved by 8-fold in Kasumi-1 cells and 2-to 20-fold in AML patient primary cells treated with GTI-2040-Tf-LPs, compared to free GTI-2040 treatment. Moreover, Tf-LPs were more effective than nontargeted LPs, with 10 to 100% improvement at various concentrations in Kasumi-1 cells and an average of 45% improvement at 3 µM concentration in AML patient primary cells. Treatment with 1 µM GTI-2040-Tf-LPs sensitized AML cells to the chemotherapy agent cytarabine, by decreasing its IC 50 value from 47.69 nM to 9.05 nM. This study suggests that the combination of pH sensitive LP formulation and Tf mediated targeting is a promising strategy for antisense ODN delivery in leukemia therapy.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous, malignant disease of the hematopoietic system characterized by clonal accumulation and expansion of immature myeloid cells in the bone marrow (BM) and blood. Mutations and overexpression of genes involved in normal patterns of cellular differentiation, proliferation and apoptosis have been discovered and correlated with the pathogenesis and prognosis of this disease. Despite the progress in the understanding of the mechanisms underlying the initiation and mainarticles 196 MOLECULAR PHARMACEUTICS VOL. 7, NO. 1, [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] tenance of this disease, only approximately 40% of the treated younger patients (aged <60 years) and <10% of older patients (aged g60 years) achieve long-term remission. 1, 2 Thus, the dismal outcome of most of the AML patients underscores a lack of significant advancements in the treatment of this disease and calls attention to the need for development of novel therapeutic strategies that specifically target abnormally functioning genes.
Cytarabine (Ara-C), a cytidine analogue, is a chemotherapy agent commonly included in treatment regimens for AML. 3, 4 It is intracellularly converted into Ara-cytidine triphosphate (Ara-CTP) and competes with the endogenous deoxycytidine triphosphate (dCTP) for incorporation into newly synthesized DNA. Once incorporated into DNA, the triphosphate metabolite inhibits DNA polymerase thereby resulting in termination of the DNA strand elongation and eventually cell death. 5, 6 Recently, ribonucleotide reductase (RNR) inhibition has shown promises to increase the cytotoxic activity of Ara-C. 7 RNR is an enzyme that catalyzes reducing ribonucleotides into deoxyribonucleotides. RNR is composed of two subunits, R1 and R2. Expression of R2 increases dramatically in late G1/early S phase, when DNA replication occurs. When overexpressed in malignant cells, RNR increases the endogenous levels of deoxyribonucleotide triphosphate (dNTP) including dCTP that compete with Ara-C and other nucleoside analogues and prevent their DNA incorporation. Conversely, RNR inhibition produces an increase in Ara-CTP/ dNTP ratio, thereby augmenting DNA incorporation of Ara-CTP, 8 and in turn enhancing cytotoxicity in proliferating malignant cells. Therefore, therapeutic strategies aimed to reduce the activity of RNR are currently being tested in the clinic with the goal of enhancing antitumor activities of nucleoside analogues.
We have recently completed a phase I study of GTI-2040, a 20-mer antisense oligodeoxyribonucleotide (ODN) that specifically hybridizes to the mRNA of the R2 subunit of RNR, 9 in combination with high-dose Ara-C in AML. 7 We showed that treatment with GTI-2040 is feasible, and combination with high-dose Ara-C appears to contribute to disease response. Although we observed downregulation at R2 mRNA and protein levels and correlation of these changes with disease response, 7 the efficiency of targeted R2 downregulation appeared to be e50% decrease in the baseline target levels following antisense exposure. Among other possible causes, we hypothesized that the low pharmacologic efficiency of GTI-2040 was due to obstacles in the ODN delivery process, 10,11 such as rapid clearance in blood circulation, poor cellular uptake, and lack of specific targeting of the "free" antisense.
( In this study, therefore, we utilized GTI-2040 to prove the principle that antisense delivery and antileukemic activity can be improved through newly devised formulations. We synthesized GTI-2040 transferrin (Tf)-conjugated PEGylated lipopolyplex nanoparticles (Tf-LPs) incorporating protamine as a DNA condensing agent, pH-sensitive fusogenic lipids to improve cytoplasmic delivery, and Tf as the targeting ligand specific for cellular delivery, which is commonly overexpressed on cancer cells including AML.
12,13 Using this delivery formulation, we showed that R2 downregulation at both mRNA and protein levels was significantly improved in AML cells treated with GTI-2040-Tf-LPs, compared to free GTI-2040 treatment. Figure 1 , an ethanol dilution method was used to prepare lipopolyplex nanoparticles (LPs) containing GTI-2040, scrambled ODNs or FAM-GTI-2040. Briefly, GTI-2040 ODNs were mixed with protamine in water at a 1:5 molar ratio for 30 min to form polyplexes. Meanwhile, a lipid mixture of DOPE/ CHEMS/PEG-DSPE at a 58:40:2 molar ratio was dissolved in ethanol and then injected into 10 mM HEPES buffer, pH 8.0, to form empty liposomes in 10% ethanol. Then, preformed empty liposomes were mixed with the protamine/ ODN suspension at a 12.5:1 lipid:ODN weight ratio, followed by vortexing and sonicating to spontaneously form LPs in the buffer solution. The final ethanol concentration articles in the cell culture was less than 1%. A postinsertion method was adopted to incorporate Tf ligand into ODN-loaded LPs.
Materials and Methods
14-17
Cryogenic Transmission Electron Microscopy (Cryo-TEM).
Cryo-TEM imaging was performed at Technion-Israel Institute of Technology, Haifa, Israel, as previously described. 18 Briefly, samples were examined in a Philips CM120 microscope (Eindhoven, The Netherlands) at 120 kV, using an Oxford CT-3500 cooling holder and transfer station (Abingdon, England). Specimens were equilibrated in the microscope below -178°C, then examined in the low-dose imaging mode to minimize electron beam radiation damage, and recorded at a nominal underfocus of 1-2 µm to enhance phase contrast. Images were acquired digitally by a Gatan MultiScan 791 cooled charge-coupled device camera (Pleasanton, CA) using the Digital Micrograph 3.1 software package.
2.5. Characterization of LPs and Evaluation of ODN Encapsulation Efficiency. The particle size of LPs was analyzed on a NICOMP Particle Sizer model 370 (Particle Sizing Systems, Santa Barbara, CA). The volume-weighted Gaussian distribution analysis was used to determine the mean vesicle diameter. The zeta potential was determined on a ZetaPALS (Brookhaven Instruments Corp., Worcestershire, NY). All measurements were carried out in triplicate. The ODN encapsulation efficiency of LPs was determined using gel electrophoresis. First, LPs were lysed with 0.5% SDS and 1% Triton X-100, followed by agarose gel electrophoresis to separate SDS, Triton, and ODNs. Meanwhile, a series of ODN standards (n ) 5) were loaded onto the agarose gel. The brightness and the expected amount of ODN of each band showed a linear correlation (correlation coefficient, R 2 ) 0.99). Using this standard curve, the amount of ODN encapsulated in the LPs was then estimated by measuring the brightness of the ODN band. Encapsulation efficiency was calculated based on the ratio of ODNs in LPs versus the initial amount of ODNs applied. This method was validated for ODN quantification with the coefficient of variation less than 5% in three repeated experiments.
2.6. Study of Tf Receptor (TfR) Expression. The expression levels of TfR (also known as CD71) on the surface of AML cells were evaluated by surface staining with PE-labeled anti-TfR (anti-CD71) monoclonal antibodies (BD Biosciences, San Jose, CA) followed by flow cytometry analysis as previously described. 15 The details are explained in the Supporting Information.
2.7. Transfection Studies. Kasumi-1 and K562 cells were seeded at 5 × 10 5 /mL density 24 h before transfection, while patient primary cells were seeded at 3 × 10 6 /mL density right after they were separated from patient BM. During the transfection, cells were exposed to LPs, Tf-LPs or free ODNs at a final concentration of 1 µM or 3 µM. In "Mock" samples, cells were treated with 10 mM HEPES buffer. After 48 h, cells were collected and analyzed for R2 mRNA level by real-time quantitative RT-PCR and for R2 protein level by Western blot.
2.8. Laser-Scanning Confocal Microscopy. Binding and internalization of FAM-GTI-2040-Tf-LPs in AML cells were examined by laser scanning confocal microscopy. Cells were incubated with FAM-GTI-2040-Tf-LPs for 0 h and 4 h respectively at 37°C and washed twice with PBS followed by fixation with 2% para-formaldehyde for 30 min. Nuclei were stained with 20 µM DRAQ5 (Biostatus Limited, Leicestershire, U.K.) for 5 min at room temperature. The cells were mounted on a poly-D-lysine coated cover glass slide (Sigma-Aldrich, St. Louis, MO). Green fluorescence of FAM-GTI-2040 and blue fluorescence of DRAQ5 were acquired, and merged images were produced by using Zeiss 510 META laser scanning confocal imaging systems and LSM Image software (Carl Zeiss MicroImaging, Inc., NY).
Quantitative RT-PCR (qRT-PCR).
The R2 mRNA level in AML cells was evaluated using qRT-PCR as previously described. 19 Primer sequences for R2 and ABL, and qRT-PCR conditions are reported in the Supporting Information.
2.10. Western Blot Analysis. The R2 protein expression was measured by Western blot as previously described. 20 Anti-R2 and anti-GAPDH antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
9 Equivalent gel loading was confirmed by probing with antibodies against GAPDH. 2.12. Statistical Analysis. Data were represented as mean ( standard deviations and analyzed by 2-tailed Student's t test using MiniTAB Program (Minitab Inc., State College, PA). p < 0.05 was considered statistically significant.
Results

Preparation and Characterization of LPs and
Tf-LPs. In order to improve the delivery and efficacy of GTI-2040, we synthesized Tf-LPs. This process is schematically illustrated in Figure 1 . Three steps were involved in the whole process: (1) Negatively charged GTI-2040 ODNs were condensed with positively charged protamine at 1:5 molar ratio in H 2 O to synthesize a polyplex nano core; (2) the polyplex nano core was then mixed with negatively charged anionic liposomes to form LPs; (3) LPs were modified with Tf-PEG-DSPEmicelles,previouslysynthesizedasdescribed, [14] [15] [16] [17] to form the final Tf-LPs targeted nanoparticles that were used for the subsequent experiments.
The nanostructures of primary components of the Tf-LP targeted nanoparticles, the polyplexes synthesized in stage 1 (Figure 2A ) and the LPs ( Figure 2B ) synthesized in stage 2, were then studied by direct nanoscale imaging via Cryo-TEM (Figure 2) . Several coexisting structures were observed, including onion-like LPs ( Figure 2B ). LPs had an average particle size of 108.5 ( 5.4 nm and a zeta potential of 12.12 ( 0.82 mV. The GTI-2040 encapsulation efficiency of LPs was determined by agarose gel electrophoresis and found to be over 90% ( Figure S1 in the Supporting Information).
TfR Expression on AML Cells and Patient Primary Cells.
Tf is the targeting molecule on Tf-LPs, which can be efficiently taken up by cells expressing TfR via TfRmediated endocytosis. 21, 22 TfR is a dimeric transmembrane glycoprotein commonly overexpressed on proliferating cells including most tumor cells.
12, 13 The expression of TfR on the surface of AML cells was studied using PE-labeled antiTfR monoclonal antibodies. Kasumi-1 cells, K562 cells and AML patient primary cells that were used in this study demonstrated high levels of cell surface TfR expression ( Figure 3A) . The expression levels of TfR on Kasumi-1, K562 and patient primary cells were further increased by pretreatment with deferoxamine (DFO) (Figure 3A) , an iron chelator known to increase TfR expression. GTI-2040-LPs ( Figure 4A ). In contrast, treatment with 3 µM Tf-LPs containing scrambled ODNs only caused 14 ( 3% R2 downregulation. A similar trend of R2 mRNA downregulation was observed ( Figure S3 in the Supporting Information). These data support more efficient cellular delivery of the antisense and downregulation of the target by GTI-2040-Tf-LPs compared to nontargeted LPs.
Despite the more efficient delivery of GTI-2040 by TfLPs, only 23% target downregulation was observed at 1 µM concentration. Nevertheless, we showed that GTI-2040 delivery by Tf-LPs was further enhanced by pretreatment with 30 µM DFO for at least 18 h ( Figure 4B ). As shown in Figure 4B , at 1 µM GTI-2040-Tf-LPs concentration, DFO pretreatment improved R2 downregulation (49 ( 4%) in Kasumi-1 cells compared to the samples without DFO pretreatment (17 ( 3%). At 3 µM GTI-2040-Tf-LP concentration, DFO pretreatment also improved the R2 downregulation from 88 ( 1% to 94 ( 1%.
3.5. R2 Downregulation by GTI-2040-Tf-LPs in AML Patient Primary Cells. GTI-2040-Tf-LPs dosedependent R2 downregulation was proven in blasts collected from two AML patients treated at our institution ( Figure 5 and Figure S4 in the Supporting Information). Blasts from a third patient were used to conduct studies of the enhancing effect of DFO ( Figure 5B ). We showed that DFO, which by itself did not have any effect on R2 expression levels under current pretreatment conditions, enhanced the antisense activity of 1 µM and 3 µM GTI-2040-Tf-LPs ( Figure 5B ). DFO pretreatment did not have any effect on R2 expression in cell treated with scrambled-Tf-LPs.
The expression levels of TfR on AML primary cells from patients 1-3 were analyzed using flow cytometry ( Figure  S5 in the Supporting Information). Patient 3 has a lower level of expression of TfR, which may explain the reduced response to Tf-LP treatment in the absence of pre-exposure to DFO.
3.6. GTI-2040-Tf-LPs Improved the Chemosensitivity of AML Cells to Ara-C. A phase I clinical trial in AML at OSU has demonstrated that GTI-2040 and high-dose Ara-C can be coadministered safely and showed reduction of R2 and promising clinical response. 7 In the current study, we sought to demonstrate that improved delivery of GTI-2040 results in an increased sensitivity to Ara-C in AML cells. We treated Kasumi-1 cells with GTI-2040-Tf-LPs, free GTI-2040 or Scrambled-Tf-LPs, followed by cell exposure to various Ara-C concentrations. Cell proliferation and survival were then evaluated by MTS assay. As shown in Figure 6 , at concentration as low as 1 µM, only GTI-2040-Tf-LPs could sensitize Kasumi-1 cells to Ara-C, with the IC 50 of Ara-C decreased by 5-fold from 47.69 nM to 9.05 nM. Free GTI-2040 and Tf-LPs containing scrambled ODNs had no chemosensitization effect, consistent with the trend observed for R2 downregulation ( Figure 4A ).
Discussion
The goal of our work is to develop formulations capable of improving targeted delivery of ODNs to specific populations of malignant cells, thereby enhancing their clinical efficacy and reduce their side effects in normal tissue. Herein, we report Tf-LPs efficiently delivered GTI-2040 into AML cells, downregulated R2, and chemosensitized the cells to Ara-C. These effects were highly sequence specific and formulation dependent, as free GTI-2040 or Tf-LPs containing scrambled ODNs showed much less or no antisense activity. Importantly, we showed that the cytotoxicity against AML cells of our novel compound was due to the delivered antisense, GTI-2040, and not to the target-LP formulation by itself.
Overcoming the delivery obstacle is the greatest challenge for ODNs in clinical application. 24, 25 A variety of vehicles have been developed to facilitate delivery of ODNs. 26 Polymers and lipids are two major classes of materials commonly used for condensing DNA/ODN into nanoparticles by forming polymer-DNA complexes (polyplexes), [27] [28] [29] [30] [31] lipid-DNA/ODNcomplexes(lipoplexes), [32] [33] [34] [35] andlipid-polymer-DNA/ODNternarycomplexes(LPs), [36] [37] [38] respectively. In this study, we developed LPs for GTI-2040 ODN delivery. 38, 40 have been conjugated to LPs to achieve specific delivery in tumor tissues expressing the corresponding antigens or receptors. Based on these properties, the LP formulation platform appears to be a promising strategy for engineering targeted multifunctional nanoparticles for ODN delivery, such as GTI-2040, and overcoming the delivery problems hitherto faced by these compounds. In our work, protamine sulfate, a clinically used polycationic peptide, was used as a good candidate of biodegradable cationic polymers. It can bind ODNs to form a compact structure via electrostatic interactions, and has been shown to facilitate DNA delivery. 41 Lipid bilayers composed of CHEMS, a pH-sensitive lipid, and DOPE, a fusogenic lipid, are known to undergo a transition from lamellar to hexagonal II phase at low pH, which can destabilize endosomes through proximity following endocytosis. 25 Therefore, LPs with these lipids are capable of releasing their contents in response to acidic pH within the endosomal system while remaining stable in plasma, thus improving the cytoplasmic delivery of ODNs after endocytosis. Tf, an 80 kDa iron-transporting glycoprotein, can be efficiently taken up by cells via TfRmediated endocytosis. 21, 22 TfR is considered a good target for cancer-specific delivery, as it is commonly overexpressed on cancer cells including AML 12,13 compared to normal cells. This was confirmed in our study ( Figure 3A ). In addition, Tf is less immunogenic and more cost-effective than monoclonal antibodies, and easy to handle and store. 42 The detailed structure of LP nanoparticles was studied with Cryo-TEM, indicating several coexisting structures, including onion-like LPs ( Figure 2B ), in which the ODNs were condensed between two adjacent lipid bilayers, empty liposomes, and amorphous complexes of protamine/ODN. Although the current LP structure is nonuniform, we are currently developing better LP synthesis methods, such as microfluidic focusing, 43 to improve the uniformity of the nanoparticle size and structure, as well as increase ODN loading with less lipids and condensing agents for better transfection efficiency and less cytotoxicity.
The marked decrease in R2 levels in cells treated with 3 µM untargeted LPs might be due to treatment with a large number of LPs. In the future, targeted LPs with a higher ODN loading and hence needing to treat cells with a lower concentration of LPs may address this. Nevertheless, another important point of Figures 4A and 5A is that, at the same concentration (3 µM), Tf-LPs performed better than untargeted LPs.
DFO is an iron chelator known to increase TfR expression. 23 This compound is already in the clinic and used for the treatment of iron overload. 44 Therefore, we would not expect any unanticipated toxicity, should it be incorporated in combination with GTI-2040-Tf-LPs in clinical programs for AML patients. Although DFO treatment may also increase the TfR expression level on normal cells, it is possible that cancer cells are more sensitive to this compound as rapidly dividing cells have an increased demand for iron. 45 In the present study, pretreatment of DFO increased TfR expression on both AML cell lines and patient primary cells, and improved the efficacy of GTI-2040-Tf-LPs. This implied that pretreatment of DFO may also improve the targeted delivery and efficacy of GTI-2040 delivered by Tf-LPs in a clinical situation. However, whether or not DFO may increase side effects on normal tissue in patients treated with GTI-2040-Tf-LPs is currently unknown and should be one of primary end points of analysis in future clinical trials.
Because of early onset of mechanisms of resistance, AML patients are commonly treated with a multidrug chemotherapy regimen. We combined here GTI-2040 with Ara-C, which represents the backbone for both upfront and salvage regimen in AML. The rationale for this combination is that the metabolite of Ara-C, Ara-CTP, incorporates into DNA and terminates DNA chain elongation by competing with the endogenous dCTP derived from RNR-mediated nucleotide reduction. [46] [47] [48] [49] It is expected that downregulation of the R2 subunit of RNR by GTI-2040 decreases the endogenous levels of dCTP and further increases the Ara-CTP/ dNTP ratio thereby augmenting DNA incorporation of Ara-CTP. 8 This combination has been studied in the phase I clinical trial at OSU, leading to promising results. 7 However, the in vivo downregulation of R2 in patients treated on this trial was only e50%. Therefore, to attain a more efficient R2 downregulation and further enhance the therapeutic efficacy of GTI-Ara-C combination, we improved the intracellular delivery of GTI-2040 by Tf-LPs. At a concentration of GTI-2040-Tf-LP as low as 1 µM, it could sensitize AML cells to Ara-C, with the IC 50 of Ara-C decreased by 5-fold, thereby further supporting the hypothesis that this combination is effective and needs to be further studied in clinical trials.
Conclusions
In summary, targeted LPs with high ODN encapsulation efficiency have been developed in this study. The GTI-2040-Tf-LPs effectively downregulated R2 expression in AML cell lines and AML patient primary cells, and chemosensitized AML cells toward Ara-C. Further preclinical evaluation and potential clinical trials for this promising formulation of GTI-2040 are warranted.
